NetworkNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Stable Across Wide Range of Temps
Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, recently completed the synthesis of its ONP-002 drug batch for its upcoming planned phase 2 clinical trial. Consequently, the company is reporting that ONP-002, its lead candidate for treating concussion, is stable across a wide temperature range, thus eliminating the need for cumbersome cold storage during transport and storage. Specifically, the company reported three-month stability with more than 99% purity at temperatures ranging from -20°C to 104°C. “We understand the importance of getting ONP-002 into the brain quickly after concussive injury to…







